Crossmark

A phase 1 randomized study compare the pharmacokinetics, safety and immunogenicity of HLX04 to reference bevacizumab sourced from the United States, the European Union, and China in healthy Chinese male volunteers

Crossref DOI link: https://doi.org/10.1007/s00280-021-04297-z

Published Online: 2021-06-04

Published Print: 2021-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zhu, Xiaoxue

Qian, Hongjie

Sun, Jixuan

Wu, Min

Yu, Chen

Ding, Yanhua

Zhang, Xiaodi

Chai, Katherine

Li, Xiaojiao https://orcid.org/0000-0002-2936-7864
Funding

Funding for this research was provided by:

Shanghai Henlius Biotech, Inc.
License Information

Text and Data Mining valid from 2021-06-04

Version of Record valid from 2021-06-04
More Information

Article History

Received: 14 December 2020

Accepted: 15 May 2021

First Online: 4 June 2021

Declarations

:

: Xiaodi Zhang and Katherine Chai are employees of Shanghai Henlius Biotech, Inc. All other authors declare no competing interests.

: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

: All participants provided written informed consent before admission and initiation of the study.

Document is current

Any future updates will be listed below